Veradermics

MANEPhase 3

New York, United Statesveradermics.com

Veradermics is a late-stage biotech targeting high-prevalence, under-innovated dermatology and aesthetics conditions, starting with pattern hair loss. The company's strategy centers on advancing novel therapeutics like VDPHL01, a proprietary extended-release oral minoxidil designed to be safer and more effective than existing options. Led by a team of dermatologists and seasoned biotech executives, Veradermics has secured significant financing and is advancing multiple Phase 3 trials, positioning itself to address a massive market with limited new prescription therapies.

Market Cap

$2.1B

Founded

2021

Focus

Small Molecules

MANE · Stock Price

USD 58.89+21.14 (+56.00%)

Historical price data

AI Company Overview

Technology Platform

Proprietary extended-release drug delivery technology focused on optimizing the pharmacokinetic and safety profiles of proven therapeutic compounds for dermatologic conditions.

Pipeline Snapshot

5 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
VDPHL01 QD + Placebo + VDPHL01 BID + Placebo	Androgenetic Alopecia (AGA)	Phase 3
VDPHL01 + Placebo	Androgenetic Alopecia	Phase 3
VDPHL01 + Placebo	Androgenetic Alopecia	Phase 2/3
VDPHL01	Androgenetic Alopecia	Phase 2
VDMN-21 Patch Low Dose + VDMN-21 Patch High Dose + Vehicle Patch	Verruca Vulgaris	Phase 2

Funding History

Total raised: $60M

Series A$50MFrazier Healthcare PartnersSep 15, 2022

Seed$10MFrazier Healthcare PartnersJun 15, 2021

Opportunities

The primary opportunity is capturing a multi-billion dollar market in pattern hair loss by offering the first convenient, non-hormonal oral therapy for both men and women.

Success with VDPHL01 would provide capital and credibility to advance a pipeline of other 'under-innovated' dermatology conditions like alopecia areata and common viral skin infections, leveraging the same dermatologist-led development model.

Risk Factors

Key risks include clinical failure of VDPHL01 in Phase 3 trials, emergence of long-term safety concerns (particularly cardiac), regulatory challenges in approving a new formulation of an old drug, and the commercial execution risk of launching a first product against entrenched competitors.

The company's value is highly concentrated in a single asset.

Competitive Landscape

Competes against the standard of care for hair loss: topical minoxidil (low efficacy, poor adherence) and oral finasteride/dutasteride (hormonal, for men only). Veradermics differentiates with VDPHL01's potential as the first non-hormonal oral prescription therapy for both genders, using a proprietary extended-release formulation designed for superior safety and efficacy compared to off-label immediate-release oral minoxidil.